Author
Listed:
- Melissa R. Junttila
(University of California San Francisco
Present addresses: Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK (C.P.M.); Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge CB2 1GA, UK (G.I.E.); Department of Molecular Biology, Genentech. Inc. South San Francisco, CA 94080 , USA (M.R.J.).)
- Anthony N. Karnezis
(University of California San Francisco)
- Daniel Garcia
(University of California San Francisco)
- Francesc Madriles
(Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre)
- Roderik M. Kortlever
(University of California San Francisco)
- Fanya Rostker
(University of California San Francisco)
- Lamorna Brown Swigart
(University of California San Francisco)
- David M. Pham
(University of California San Francisco)
- Youngho Seo
(University of California San Francisco)
- Gerard I. Evan
(University of California San Francisco
Present addresses: Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK (C.P.M.); Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge CB2 1GA, UK (G.I.E.); Department of Molecular Biology, Genentech. Inc. South San Francisco, CA 94080 , USA (M.R.J.).)
- Carla P. Martins
(University of California San Francisco
Present addresses: Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK (C.P.M.); Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge CB2 1GA, UK (G.I.E.); Department of Molecular Biology, Genentech. Inc. South San Francisco, CA 94080 , USA (M.R.J.).)
Abstract
Limits to antitumour effect of p53 restoration Inactivation of the p53 tumour-suppressor pathway is a common feature of human cancers, prompting suggestions that restoring p53 function in established tumours might be an effective therapy. However, two papers in this week's Nature highlight a practical limitation of p53-directed cancer therapeutics. They show in a K-Ras-driven lung-cancer model that p53-mediated tumour suppression is engaged only at a late stage of tumour progression, when the K-Ras oncogenic signal reaches a threshold that is sufficient to activate the ARF-p53 pathway. This means that p53 re-expression fails to restrict the early stages of tumorigenesis, although it does induce regression of more aggressive tumours.
Suggested Citation
Melissa R. Junttila & Anthony N. Karnezis & Daniel Garcia & Francesc Madriles & Roderik M. Kortlever & Fanya Rostker & Lamorna Brown Swigart & David M. Pham & Youngho Seo & Gerard I. Evan & Carla P. M, 2010.
"Selective activation of p53-mediated tumour suppression in high-grade tumours,"
Nature, Nature, vol. 468(7323), pages 567-571, November.
Handle:
RePEc:nat:nature:v:468:y:2010:i:7323:d:10.1038_nature09526
DOI: 10.1038/nature09526
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:468:y:2010:i:7323:d:10.1038_nature09526. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.